DELALOGE , S.

Background: Real-world data (RWD) can contextualize clinical trial data. We present real-world evidence thatsupplemented the single-arm DESTINY-Breast01 trial, which assessed the efficacy and safety of trastuzumabderuxtecan (T-DXd) in patients with human epidermal growth factor receptor 2-positive (HER2þ) metastatic breastcancer (mBC)...

BACKGROUND:For hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC), international guidelines recommend endocrine therapy as first-line treatment, except in case of 'visceral crisis'. In the latter case, chemotherapy is preferred. Few studies have compared these two strategies....

BACKGROUND: Treatment strategies for metastatic breast cancer (MBC) have made great strides over the past 10 years. Real-world data allow us to evaluate the actual benefit of new treatments. ESME (Epidemio-Strategy-Medico-Economical)-MBC, a nationwide observational cohort (NCT03275311), gathers data of all consecutive MBC patients who initiated...